Pfizer and PostEra Partner to Apply Machine Learning in Drug Discovery
Pfizer has entered a multi-year partnership with biotechnology firm PostEra to integrate machine learning and generative chemistry into its preclinical drug discovery process.
Pfizer has finalized a strategic agreement with PostEra to accelerate the development of small molecule therapeutics using advanced machine learning. The collaboration combines Pfizer’s large-scale research data with PostEra’s technology, which focuses on designing novel molecular structures that account for chemical synthesis constraints and medicinal chemistry requirements.
By deploying these generative chemistry models, Pfizer intends to refine its preclinical workflow, aiming to improve the potency and drug-like properties of new candidates. The initiative represents a broader industry trend toward utilizing artificial intelligence to streamline early-stage research and reduce development timelines.
PostEra, a startup founded in 2019, will receive an upfront payment and potential performance-based milestones. The company retains ownership of the algorithms created throughout the project, while Pfizer gains access to the platform for its internal drug discovery efforts.